Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
8.49
Oct 23 • 3:58 PM ET Dollar change+0.01 Percentage change(0.12%)
Aftermarket Close
7.50
Aftermarket • 7:42 PM ET Dollar change-0.99 Percentage change(-11.66%)
Oct 23, 4:10 PMCumberland reports Phase 2a ASSIST-SSc top-line data: oral ifetroban generally well tolerated with limited disease progression, no efficacy conclusions yet
Index
-
Market Cap
127.21M
Enterprise Value
127.73M
Income
-10.92M
Sales
31.27M
Book/sh
1.16
Cash/sh
0.26
Employees
93
IPO
Aug 11, 2009
P/E
-
Forward P/E
-
PEG
-
P/S
4.07
P/B
7.29
P/C
32.96
P/FCF
187.07
EV/EBITDA
-
EV/Sales
4.08
Quick Ratio
0.96
Current Ratio
0.96
Debt/Eq
0.27
LT Debt/Eq
0.24
Option/Short
Yes / Yes
EPS (ttm)
-0.73
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
20.68% 2.82%
Sales past 3/5Y
1.95% 3.52%
EPS Y/Y TTM
-244.92%
Sales Y/Y TTM
-25.68%
EPS Q/Q
-476.57%
Sales Q/Q
-98.46%
Insider Own
41.60%
Insider Trans
0.00%
Inst Own
16.57%
Inst Trans
-6.87%
ROA
-14.91%
ROE
-42.92%
ROIC
-50.43%
Gross Margin
86.22%
Oper. Margin
-29.58%
Profit Margin
-34.92%
SMA20
13.65%
SMA50
14.36%
SMA200
77.67%
Trades
Shs Outstand
14.98M
Shs Float
8.75M
52W High
9.28 -8.51%
52W Low
1.43 491.81%
Volatility
11.37% 8.06%
ATR (14)
0.60
RSI (14)
63.99
Beta
0.10
Rel Volume
0.56
Avg Volume
79.52K
Volume
44,319
Perf Week
18.25%
Perf Month
5.99%
Perf Quarter
55.74%
Perf Half Y
169.67%
Perf YTD
175.09%
Perf Year
211.92%
Perf 3Y
444.70%
Perf 5Y
308.53%
Perf 10Y
122.08%
Prev Close
8.48
Price
8.49
Change %
0.12%
Date Action Analyst Rating Change Price Target Change
Nov-12-12Reiterated UBS Neutral $6.50 → $5
Feb-01-11Reiterated UBS Neutral $8 → $6.50
Dec-16-10Downgrade UBS Buy → Neutral $10 → $8
Aug-17-10Reiterated UBS Buy $11 → $10
Aug-17-10Reiterated Morgan Joseph Buy $15 → $10
Aug-17-10Downgrade Jefferies Buy → Hold $13 → $5.50
May-14-10Reiterated Morgan Joseph Buy $21 → $15
Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. It operates through the following geographical segments: China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The firm products include Acetadote, Caldolor, Kristalose, Vaprisol, Talicia, Vibativ, Sancuso, Omeclamox, RediTrex, and Other. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.
FounderMr. A. J. Kazimi MBA
Vice President Accounting & Finance and CFOMr. John Michael Hamm C.M.A.
Vice President of Organizational DevelopmentMr. Todd M. Anthony
Managing Director of Banking & Investor RelationsMr. Adam S. Mostafa